VIRTUAL EVENT
Lung Cancer is the leading cause of cancer death worldwide. It is difficult to detect in its early stages, as well as understand and treat effectively.
Lung cancer R&D is experiencing rapid growth, representing an enormous opportunity for drug developers, with a 22% rise in new candidates in 2015.
The global market for Lung cancer therapeutics, currently valued at $5 billion is poised to reach $15.1 billion by 2023, expanding by a CAGR of 12%
Do You Have the Latest Insights to Transform the Success of Your Pipeline?
Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.
Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
HIGHLIGHTS
ANTIBODY CONSTRUCTS
IMMUNOTHERAPY
NOVEL APPROACHES
BIOMARKERS
COMPANION DIAGNOSTICS
32%
26%
14%
12%
9%
7%
Large Drug Developers
Small & Mid-Sized Developers
Academia
& Hospitals
CROs &
Platform Technology
Equipment
Providers
Other
COMPANY TYPE
%
JOB TITLE
%
VP, Director, Head
C-Level
Scientists
Managers
48%
23%
18%
11%
GOALS OF THE EVENT
Learning Objectives
Target Audience
MARY-LEE DEQUEANT
Senior Scientist
CRISPR Therapeutics
JULIANN CHMIELECKI
Assoc. Dir. Translational Science
AstraZeneca
JASON CHRISTIANSEN
Chief Technology Officer
Boundless Bio
Kevin Coleman
Exec. Dir. Translational R&D
TESARO / GSK
STEPHEN MILLER
VP, Translational Medicine
Blueprint Medicines
RAMON MOHANLAL
EVP, R&D and CMO
BeyondSpring
ITALIA GRENGA
Medical Director
EMD Serono, Inc.
RACHAEL BRAKE
Global Program Lead / VP Takeda Oncology
VIEW FULL AGENDA
DOWNLOAD PDF
INDUSTRY DELEGATE
Rate Expires on 4 October 2019
Standard Rate of $2199 to Apply Thereafter
Register Now to Save
$1899
(Save $300)
BUY NOW
ACADEMIC DELEGATE
Rate Expires on 4 October 2019
Standard Rate of $799 to Apply Thereafter
Reserved for Non-Profit Organizations. Register Now to Save
$599
(Save $300)
BUY NOW
Wyndam Boston Beacon Hill
5 Blossom St, Boston, MA 02114, USA
Copyright © 2018 | All content produced by: neo-synth ltd.
Jan 25-26 2022
Virtual this year. Click below to visit the online agenda
An exclusive, annual biopharma summit providing insights into the research and development of cutting edge treatments for Lung Cancer and a networking forum for precision medicine leaders in this space.
Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.
HIGHLIGHTS
ANTIBODY DRUG CONJUGATES
IMMUNOTHERAPIES
NOVEL APPROACHES
BIOMARKERS
COMPANION DIAGNOSTICS
Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
ITALIA GRENGA
Medical Director
EMD Serono
MARY-LEE DEQUEANT
Senior Scientist
CRISPR THERAPEUTICS
STEPHEN MILLER
VP, Translational Medicine
Blueprint Therapeutics
RAMON MOHANLAL
CMO
BeyondSpring
Wyndam Boston Beacon Hill
5 Blossom St, Boston, MA 02114, USA
DOWNLOAD GUIDE